These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 38026944)

  • 1. Resistance to immune checkpoint inhibitors in gastric cancer.
    Liu K; Yuan S; Wang C; Zhu H
    Front Pharmacol; 2023; 14():1285343. PubMed ID: 38026944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Future of immune checkpoint inhibitors: focus on tumor immune microenvironment.
    Jia Y; Liu L; Shan B
    Ann Transl Med; 2020 Sep; 8(17):1095. PubMed ID: 33145314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers for Predicting Response to Personalized Immunotherapy in Gastric Cancer.
    Kim M; Jeong JY; Seo AN
    Diagnostics (Basel); 2023 Aug; 13(17):. PubMed ID: 37685320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: A multiplex immunohistochemistry-based single-cell analysis.
    Isomoto K; Haratani K; Tsujikawa T; Makutani Y; Kawakami H; Takeda M; Yonesaka K; Tanaka K; Iwasa T; Hayashi H; Ito A; Nishio K; Nakagawa K
    Lung Cancer; 2022 Dec; 174():71-82. PubMed ID: 36347190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitor resistance in hepatocellular carcinoma.
    Wang Z; Wang Y; Gao P; Ding J
    Cancer Lett; 2023 Feb; 555():216038. PubMed ID: 36529238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?
    Ziogas DC; Theocharopoulos C; Koutouratsas T; Haanen J; Gogas H
    Cancer Treat Rev; 2023 Feb; 113():102499. PubMed ID: 36542945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenosine signaling: Optimal target for gastric cancer immunotherapy.
    Wang J; Du L; Chen X
    Front Immunol; 2022; 13():1027838. PubMed ID: 36189223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor.
    Bai X; Yi M; Jiao Y; Chu Q; Wu K
    Onco Targets Ther; 2019; 12():9527-9538. PubMed ID: 31807028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance.
    Santiago-Sánchez GS; Fabian KP; Hodge JW
    Cancer Biol Ther; 2024 Dec; 25(1):2308097. PubMed ID: 38306161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status of immune checkpoint inhibitors for gastric cancer.
    Kono K; Nakajima S; Mimura K
    Gastric Cancer; 2020 Jul; 23(4):565-578. PubMed ID: 32468420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance.
    Bagchi S; Yuan R; Engleman EG
    Annu Rev Pathol; 2021 Jan; 16():223-249. PubMed ID: 33197221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations.
    Remon J; Passiglia F; Ahn MJ; Barlesi F; Forde PM; Garon EB; Gettinger S; Goldberg SB; Herbst RS; Horn L; Kubota K; Lu S; Mezquita L; Paz-Ares L; Popat S; Schalper KA; Skoulidis F; Reck M; Adjei AA; Scagliotti GV
    J Thorac Oncol; 2020 Jun; 15(6):914-947. PubMed ID: 32179179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms.
    Wang B; Han Y; Zhang Y; Zhao Q; Wang H; Wei J; Meng L; Xin Y; Jiang X
    Cell Biosci; 2023 Jun; 13(1):120. PubMed ID: 37386520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in clinical immunotherapy for gastric cancer.
    Li K; Zhang A; Li X; Zhang H; Zhao L
    Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188615. PubMed ID: 34403771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Angiopoietin-2 and TIE Pathway as a Therapeutic Target for Enhancing Antiangiogenic Therapy and Immunotherapy in Patients with Advanced Cancer.
    Leong A; Kim M
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33217955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course.
    Haryal A; Townsend MJ; Baskaran V; Srivoleti P; Giobbie-Hurder A; Sack JS; Isidro RA; LeBoeuf NR; Buchbinder EI; Hodi FS; Grover S
    Cancer; 2023 Feb; 129(3):367-375. PubMed ID: 36377339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Research status on immunotherapy trials of gastric cancer.
    Liang C; Wu HM; Yu WM; Chen W
    World J Clin Cases; 2021 Jul; 9(21):5782-5793. PubMed ID: 34368297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory T cells in gastric cancer: Key controllers from pathogenesis to therapy.
    Negura I; Pavel-Tanasa M; Danciu M
    Cancer Treat Rev; 2023 Nov; 120():102629. PubMed ID: 37769435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status of immunotherapy in gastrointestinal malignancies.
    Lorenzen S; Lordick F; Loosen SH; Tacke F; Trautwein C; Roderburg C; Ettrich TJ; Perkhofer L; Reinacher-Schick A; Stein A
    Z Gastroenterol; 2020 Jun; 58(6):542-555. PubMed ID: 32018315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer.
    Zhang Y; Yang Y; Chen Y; Lin W; Chen X; Liu J; Huang Y; Wang H; Teng L
    Front Immunol; 2022; 13():1060497. PubMed ID: 36505487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.